Literature DB >> 22368525

Ezogabine AKA Retigabine: Is More Better? Trying to Find the Right Dose From Clinical Trials.

Cynthia L Harden.   

Abstract

Entities:  

Year:  2012        PMID： 22368525      PMCID： PMC3280469          DOI： 10.5698/1535-7511-12.1.27

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  3 in total

1.  Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

Authors:  J A French; B W Abou-Khalil; R F Leroy; E M T Yacubian; P Shin; S Hall; H Mansbach; V Nohria
Journal:  Neurology       Date:  2011-03-30       Impact factor: 9.910

2.  Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

Authors:  M J Brodie; H Lerche; A Gil-Nagel; C Elger; S Hall; P Shin; V Nohria; H Mansbach
Journal:  Neurology       Date:  2010-10-13       Impact factor: 9.910

3.  Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats.

Authors:  Tomi Streng; Thomas Christoph; Karl-Erik Andersson
Journal:  J Urol       Date:  2004-11       Impact factor: 7.450
  3 in total
  2 in total

Review 1.  New antiepileptic medication linked to blue discoloration of the skin and eyes.

Authors:  Sarah Clark; Alexandra Antell; Kimberly Kaufman
Journal:  Ther Adv Drug Saf       Date:  2015-02

Review 2.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.